Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 697

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Drugging p53 in cancer: one protein, many targets

Hassin, Ori, Oren, Moshe·2023·Nature Reviews Drug Discovery
DOI 10.1038/s41573-022-00571-8
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-022-00571-8

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 138

  1. Barbosa, A. et al. Gene panel tumor testing in ovarian cancer patients significantly increases the yield of clinically actionable germline variants beyond BRCA1/BRCA2. Cancers 12, 2834 (2020). · DOI
  2. Hoe, K. K., Verma, C. S. & Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217–236 (2014). · DOI · Paper page
  3. Bykov, V. J. N., Eriksson, S. E., Bianchi, J. & Wiman, K. G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 182, 89–102 (2017).
  4. Cheok, C. F. & Lane, D. P. Exploiting the p53 pathway for therapy. Cold Spring Harb. Perspect. Med. 7, a026310 (2017). · DOI
  5. Levine, A. J. p53: 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer 20, 471–480 (2020). · DOI · Paper page
  6. Kastan, M. B., Canman, C. E. & Leonard, C. J. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 14, 3–15 (1995). · DOI · Paper page
  7. Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017). · DOI · Paper page
  8. Speidel, D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol. 20, 14–24 (2010). · DOI · Paper page
  9. Vaseva, A. V. & Moll, U. M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 1787, 414 (2009). · DOI · Paper page
  10. Giorgi, C. et al. p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner. Proc. Natl Acad. Sci. USA 112, 1779–1784 (2015). · DOI · Paper page
  11. Maiuri, M. C. et al. Autophagy regulation by p53. Curr. Opin. Cell Biol. 22, 181–185 (2010). · DOI · Paper page
  12. Tan, X. et al. p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi. Sci. Adv. 7, eabf4885 (2021). · DOI
  13. Mantovani, F., Collavin, L. & Del Sal, G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 26, 199–212 (2018). · DOI · Paper page
  14. Sicari, D. et al. Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6. Oncogene 38, 6184–6195 (2019). · DOI
  15. Capaci, V. et al. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nat. Commun. 11, 3945 (2020). · DOI
  16. Weisz, L., Oren, M. & Rotter, V. Transcription regulation by mutant p53. Oncogene 26, 2202–2211 (2007). · DOI · Paper page
  17. Kim, M. P. & Lozano, G. Mutant p53 partners in crime. Cell Death Differ. 25, 161–168 (2018). · DOI · Paper page
  18. Wellenstein, M. D. et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572, 538–542 (2019). This paper shows that p53 loss in cancer cells promotes a tumour-supportive immune microenvironment in multiple mouse models of breast cancer. · DOI · Paper page
  19. Cooks, T. et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018). · DOI · Paper page
  20. Pilley, S., Rodriguez, T. A. & Vousden, K. H. Mutant p53 in cell-cell interactions. Genes Dev. 35, 433–448 (2021). · DOI · Paper page
  21. Shchors, K. et al. Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. Proc. Natl Acad. Sci. USA 110, E1480–E1489 (2013). · DOI
  22. Sánchez-Rivera, F. J. et al. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc. Natl Acad. Sci. USA 118, e2019740118 (2021). · DOI
  23. Foster, B. A., Coffey, H. A., Morin, M. J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999). · DOI · Paper page
  24. Wang, W., Takimoto, R., Rastinejad, F. & El-Deiry, W. S. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell. Biol. 23, 2171–2181 (2003). · DOI · Paper page
  25. Rippin, T. M. et al. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21, 2119–2129 (2002). · DOI · Paper page
  26. Bykov, V. J. N. et al. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front. Oncol. 6, 21 (2016). · DOI · Paper page
  27. Chipuk, J. E., Maurer, U., Green, D. R. & Schuler, M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4, 371–381 (2003). · DOI · Paper page
  28. Saha, M. N., Chen, Y., Chen, M. H., Chen, G. & Chang, H. Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. Br. J. Cancer 110, 2224–2231 (2014). · DOI
  29. Zache, N. et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2, 70–80 (2008). · DOI · Paper page
  30. Bou-Hanna, C. et al. Acute cytotoxicity of MIRA-1/NSC19630, a mutant p53-reactivating small molecule, against human normal and cancer cells via a caspase-9-dependent apoptosis. Cancer Lett. 359, 211–217 (2015). · DOI
  31. Tal, P. et al. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget 7, 11817–11837 (2016). · DOI · Paper page
  32. Ali, D. et al. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur. J. Haematol. 86, 206–215 (2011). · DOI · Paper page
  33. Zandi, R. et al. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 17, 2830–2841 (2011). · DOI · Paper page
  34. Liu, X. et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 41, 6034–6044 (2013). · DOI · Paper page
  35. Cluzeau, T. et al. Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J. Clin. Oncol. 39, 1575–1583 (2021). · DOI · Paper page
  36. Kravchenko, J. E. et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl Acad. Sci. USA 105, 6302–6307 (2008). · DOI · Paper page
  37. Zhang, S. et al. Small-molecule NSC59984 restores p53 pathway signaling and antitumor effects against colorectal cancer via p73 activation and degradation of mutant p53. Cancer Res. 75, 3842–3852 (2015). · DOI
  38. Xu, J. et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 7, 285–295 (2011). · DOI · Paper page
  39. Zhang, S., Zhou, L. & El-Deiry, W. S. Small-molecule NSC59984 induces mutant p53 degradation through a ROS–ERK2–MDM2 axis in cancer cells. Mol. Cancer Res. 20, 622–636 (2022). · DOI
  40. Wang, G. & Fersht, A. R. Propagation of aggregated p53: cross-reaction and coaggregation vs. seeding. Proc. Natl Acad. Sci. USA 112, 2443 (2015). · DOI · Paper page
  41. Palanikumar, L. et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat. Commun. 12, 3962 (2021). · DOI · Paper page
  42. Joerger, A. C., Ang, H. C. & Fersht, A. R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc. Natl Acad. Sci. USA 103, 15056–15061 (2006). · DOI · Paper page
  43. Boeckler, F. M. et al. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl Acad. Sci. USA 105, 10360–10365 (2008). · DOI · Paper page
  44. Yu, X., Vazquez, A., Levine, A. J. & Carpizo, D. R. Allele-specific p53 mutant reactivation. Cancer Cell 21, 614–625 (2012). · DOI · Paper page
  45. Yu, X. et al. Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53. Mol. Pharmacol. 91, 567–575 (2017). · DOI · Paper page
  46. Salim, K. Y., Maleki Vareki, S., Danter, W. R. & Koropatnick, J. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7, 41363–41379 (2016). · DOI · Paper page
  47. Lindemann, A. et al. COTI-2, a novel thiosemicarbazone derivative, exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. Clin. Cancer Res. 25, 5650–5662 (2019). · DOI · Paper page
  48. Westin, S. N. et al. Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer. Cancer Res. 78, CT033 (2018). · doi:10.1158/1538-7445.am2018-ct033
  49. Chen, S. et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell 39, 225–239.e8 (2021). This paper reports that ATO, used for treating acute promyelocytic leukaemia, can reactivate structural p53 mutants and induce p53-dependent tumour suppression. · DOI · Paper page
  50. Vu, B. et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 4, 466–469 (2013). · DOI · Paper page
  51. Andreeff, M. et al. Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin. Cancer Res. 22, 868 (2016). · DOI · Paper page
  52. Kim, E. S. & Shohet, J. M. Reactivation of p53 via MDM2 inhibition. Cell Death Dis. 6, e1936 (2015). · DOI
  53. Xue, Y. et al. Bortezomib stabilizes and activates p53 in proliferative compartments of both normal and tumor tissues in vivo. Cancer Res. 79, 3595–3607 (2019). · DOI
  54. Yee, K. et al. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: results from an idasanutlin phase 1/1b study. Leuk. Res. 100, 106489 (2021). · DOI
  55. Montesinos, P. et al. MIRROS: a randomized, placebo-controlled, phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol. 16, 807–815 (2020). · DOI
  56. Konopleva, M. Y. et al. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 6, 4147–4156 (2022).
  57. Mascarenhas, J. et al. Oral idasanutlin in patients with polycythemia vera. Blood 134, 525–533 (2019). · DOI · Paper page
  58. Mascarenhas, J. et al. Safety and efficacy of idasanutlin in patients (pts) with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV): results of an international phase II study. Blood 136, 29–31 (2020). · doi:10.1182/blood-2020-135868
  59. Yi, H. et al. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. J. Exp. Clin. Cancer Res. 37, 97 (2018). · DOI · Paper page
  60. Verstovsek, S. et al. BOREAS: a global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF). J. Clin. Oncol. 39 (suppl.15), TPS7057 (2021). · DOI
  61. Erba, H. P. et al. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. Blood Adv. 3, 1939–1949 (2019). · DOI · Paper page
  62. Gounder, M. M. et al. A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas. J. Clin. Oncol. 34 (suppl.15), 2581 (2016). · DOI
  63. Tan, Y. S., Lane, D. P. & Verma, C. S. Stapled peptide design: principles and roles of computation. Drug. Discov. Today 21, 1642–1653 (2016). · DOI
  64. Bernal, F. et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18, 411–422 (2010). · DOI · Paper page
  65. Li, Y. C. et al. A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time. Cell Rep. 9, 1946–1958 (2014). · DOI · Paper page
  66. Chang, Y. S. et al. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl Acad. Sci. USA 110, E3445–E3454 (2013). · DOI · Paper page
  67. Meric-Bernstam, F. et al. Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. J. Clin. Oncol. 35, 2505 (2017). · DOI · Paper page
  68. Cheng, X. et al. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors. Nat. Commun. 13, 1087 (2022). · DOI
  69. Mares, A. et al. Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2. Commun. Biol. 3, 140 (2020). · DOI · Paper page
  70. Wang, B. et al. Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries. Eur. J. Med. Chem. 219, 113425 (2021). · DOI · Paper page
  71. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321–1328 (2004). · DOI · Paper page
  72. Zhao, C. Y., Szekely, L., Bao, W. & Selivanova, G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res. 70, 3372–3381 (2010). · DOI
  73. Weilbacher, A., Gutekunst, M., Oren, M., Aulitzky, W. E. & Van Der Kuip, H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 5, e1318 (2014). · DOI
  74. Wiegering, A. et al. Reactivating p53 and inducing tumor apoptosis (RITA) enhances the response of RITA-sensitive colorectal cancer cells to chemotherapeutic agents 5-fluorouracil and oxaliplatin. Neoplasia 19, 301–309 (2017). · DOI
  75. Yang, J. et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol. Cell. Biol. 29, 2243–2253 (2009). · DOI
  76. Celegato, M. et al. A novel small-molecule inhibitor of the human papillomavirus E6–p53 interaction that reactivates p53 function and blocks cancer cells growth. Cancer Lett. 470, 115–125 (2020). · DOI
  77. Zhang, J. et al. A small-molecule inhibitor of MDMX suppresses cervical cancer cells via the inhibition of E6–E6AP–p53 axis. Pharmacol. Res. 177, 106128 (2022). · DOI
  78. Donehower, L. A. et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep. 28, 1370–1384.e5 (2019). · DOI · Paper page
  79. Bidou, L., Bugaud, O., Belakhov, V., Baasov, T. & Namy, O. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biol. 14, 378–388 (2017). · DOI · Paper page
  80. Floquet, C., Deforges, J., Rousset, J. P. & Bidou, L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res. 39, 3350–3362 (2011). · DOI · Paper page
  81. Martin, L. et al. Identification and characterization of small molecules that inhibit nonsense-mediated rna decay and suppress nonsense p53 mutations. Cancer Res. 74, 3104–3113 (2014). · DOI
  82. Dabrowski, M., Bukowy-Bieryllo, Z. & Zietkiewicz, E. Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons. Mol. Med. 24, 25 (2018). · DOI · Paper page
  83. Alexandrova, E. M. et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356 (2015). · DOI · Paper page
  84. Padmanabhan, A. et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat. Commun. 9, 1270 (2018). · DOI · Paper page
  85. Hassin, O. et al. Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients. Nat. Commun. 13, 2800 (2022). · DOI
  86. Mukherjee, S. et al. Cross-talk between mutant p53 and p62/SQSTM1 augments cancer cell migration by promoting the degradation of cell adhesion proteins. Proc. Natl Acad. Sci. USA 119, e2119644119 (2022). · DOI
  87. Kennedy, M. C. & Lowe, S. W. Mutant p53: it’s not all one and the same. Cell Death Differ. 29, 983–987 (2022). · DOI · Paper page
  88. Alvarado-Ortiz, E. et al. Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches. Front. Cell Dev. Biol. 8, 607670 (2021). · DOI
  89. Lauwen, M. M. et al. Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. Cancer Res. 68, 893–900 (2008). · DOI
  90. Chikamatsu, K. et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res. 5, 1281–1288 (1999).
  91. Röpke, M. et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl Acad. Sci. USA 93, 14704–14707 (1996). · DOI
  92. Vierboom, M. P. M. et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186, 695–704 (1997). · DOI · Paper page
  93. Speetjens, F. M. et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15, 1086–1095 (2009). · DOI · Paper page
  94. Vermeij, R. et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int. J. Cancer 131, E670–E680 (2012). · DOI · Paper page
  95. Hardwick, N. R. et al. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses. Clin. Cancer Res. 20, 4459–4470 (2014). · DOI · Paper page
  96. Barfoed, A. M. et al. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand. J. Immunol. 51, 128–133 (2000). · DOI · Paper page
  97. Antonia, S. J. et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12, 878–887 (2006). · DOI · Paper page
  98. Low, L., Goh, A., Koh, J., Lim, S. & Wang, C. I. Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen. Nat. Commun. 10, 5382 (2019). · DOI · Paper page
  99. Cheever, M. A. et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323–5337 (2009). · DOI · Paper page
  100. Deniger, D. C. et al. T-cell responses to TP53 ‘Hotspot’ mutations and unique neoantigens expressed by human ovarian cancers. Clin. Cancer Res. 24, 5562–5573 (2018). · DOI
  101. Malekzadeh, P. et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J. Clin. Invest. 129, 1109–1114 (2019). · DOI · Paper page
  102. Malekzadeh, P. et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clin. Cancer Res. 26, 1267–1276 (2020). · DOI
  103. You, G. et al. Bispecific antibodies: a smart arsenal for cancer immunotherapies. Vaccines 9, 724 (2021). · DOI
  104. Cortez, M. A. et al. PDL1 regulation by p53 via miR-34. J. Natl Cancer Inst. 108, djv303 (2015). This paper reports that wtp53 can downregulate PDL1 in cancer cells, suggesting a mechanism whereby loss of wtp53 can render such cells more refractory to immune attack.
  105. Zhou, X. et al. Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity. Cancer Discov. 11, 3090–3105 (2021). · DOI · Paper page
  106. Maddalena, M. et al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc. Natl Acad. Sci. USA 118, e2025631118 (2021). · DOI
  107. Moskovits, N., Kalinkovich, A., Bar, J., Lapidot, T. & Oren, M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 66, 10671–10676 (2006). · DOI
  108. Kim, S.-S., Harford, J. B., Moghe, M., Rait, A. & Chang, E. H. Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. Oncoimmunology 7, e1484982 (2018). · DOI
  109. Chada, S. et al. Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer Gene Ther. 29, 825–834 (2022). · DOI
  110. Wang, D. & Wang, K. An overview of development in gene therapeutics in China. Gene Ther. 27, 338–348 (2020). · DOI
  111. Goswami, R. et al. Gene therapy leaves a vicious cycle. Front. Oncol. 9, 297 (2019). · DOI · Paper page
  112. Zhang, W. W. et al. The first approved gene therapy product for cancer ad-p53 (gendicine): 12 years in the clinic. Hum. Gene Ther. 29, 160–179 (2018). · DOI · Paper page
  113. Xia, Y., Du, Z., Wang, X. & Li, X. Treatment of uterine sarcoma with rAd-p53 (gendicine) followed by chemotherapy: clinical study of TP53 gene therapy. Hum. Gene Ther. 29, 242–250 (2018). · DOI
  114. Li, Y. et al. Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial. BMC Med. 12, 16 (2014). · doi:10.1186/1741-7015-12-16
  115. Liu, S. et al. Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer. Cancer Gene Ther. 20, 375–378 (2013). · doi:10.1038/cgt.2013.30
  116. Gabrilovich, D. I. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin. Biol. Ther. 6, 823–832 (2006). · DOI
  117. Atencio, I. A. et al. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a phase 1 colorectal cancer trial. Cancer Gene Ther. 13, 169–181 (2006). · DOI
  118. Buller, R. E. et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 9, 553–566 (2002). · DOI · Paper page
  119. Zeimet, A. G. & Marth, C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 4, 415–422 (2003). · DOI
  120. Li, Y. et al. Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers. Int. J. Oral. Sci. 13, 38 (2021). · DOI
  121. Tamura, R. E. et al. Induction of oxidants distinguishes susceptibility of prostate carcinoma cell lines to p53 gene transfer mediated by an improved adenoviral vector. Hum. Gene Ther. 28, 639–653 (2017). · DOI
  122. Chen, S. et al. A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy. Biomaterials 77, 149–163 (2016). · DOI
  123. Misra, S. K., Naz, S., Kondaiah, P. & Bhattacharya, S. A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer cells. Biomaterials 35, 1334–1346 (2014). · DOI
  124. Rejeeth, C. & Kannan, S. p53 Gene therapy of human breast carcinoma: using a transferrin-modified silica nanoparticles. Breast Cancer 23, 101–110 (2016). · DOI
  125. Kim, S. S., Rait, A., Kim, E., Pirollo, K. F. & Chang, E. H. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 11, 301–311 (2015). · DOI
  126. Senzer, N. et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 21, 1096–1103 (2013). · DOI · Paper page
  127. Pirollo, K. F. et al. Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: a phase 1b study. Mol. Ther. 24, 1697–1706 (2016). · DOI
  128. Xiao, Y. et al. Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy. Nat. Commun. 13, 758 (2022). · DOI · Paper page
  129. Sobol, R. E. et al. Meta-analysis of adenoviral p53 gene therapy clinical trials in recurrent head and neck squamous cell carcinoma. medRxiv https://doi.org/10.1101/2021.01.06.20248743 (2021). · doi:10.1101/2021.01.06.20248743
  130. Mirgayazova, R. et al. Therapeutic editing of the TP53 gene: is CRISPR/Cas9 an option? Genes 11, 704 (2020). · DOI
  131. Ihry, R. J. et al. p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells. Nat. Med. 24, 939–946 (2018). · DOI · Paper page
  132. Enache, O. M. et al. Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat. Genet. 52, 662–668 (2020). · DOI · Paper page
  133. Latif, A. L. et al. BRD4-mediated repression of p53 is a target for combination therapy in AML. Nat. Commun. 12, 241 (2021). · DOI
  134. Pan, R. et al. Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: mechanisms and superior antileukemic efficacy. Cancer Cell 32, 748–760.e6 (2017). · DOI · Paper page
  135. Daver, N. G. et al. Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or refractory (R/R) AML: a phase Ib, non-randomized, open-label study. Blood 132, 767–767 (2018). · doi:10.1182/blood-2018-99-116013
  136. Fischer, M. Mice are not humans: the case of p53. Trends Cancer 7, 12–14 (2021). · DOI
  137. Horejs, C. Organ chips, organoids and the animal testing conundrum. Nat. Rev. Mater. 6, 372–373 (2021). · DOI
  138. Gavert, N. et al. Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. Nat. Cancer 3, 219–231 (2022). · DOI

Cited by

See all 697

Metadata

Authors
Hassin, O., & Oren, M.
ORCID
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2022-10-10
Volume
22
Issue
2
Pages
127-144
ISSN
  • 1474-1776
  • 1474-1784
DOI
10.1038/s41573-022-00571-8
Cited by
697
References
54
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drugging p53 in cancer: one protein, many targets. https://app.cochat.ai/papers/10.1038/s41573-022-00571-8
The paper
Hassin, O., & Oren, M. (2023). Drugging p53 in cancer: one protein, many targets. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-022-00571-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.